Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18651454 | COMPOSITIONS CONTAINING SHORT-CHAIN FATTY ACID, METHODS OF USE, AND METHODS OF MAKING THEREOF | April 2024 | November 2024 | Allow | 7 | 2 | 0 | Yes | No |
| 18600301 | TREATING SAR-COV-2 RELATED HEALTH PROBLEMS | March 2024 | May 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18533052 | WOUND DRESSING BASED ON POLYMERIC MIXTURE OF CELLULOSE ACETATE AND HYALURONIC ACID EMBEDDED WITH COPPER OXIDE AND MAGNESIUM OXIDE NANOPARTICLES | December 2023 | December 2024 | Allow | 12 | 2 | 0 | No | No |
| 18244012 | WOUND DRESSING BASED ON POLYMERIC MIXTURE OF CELLULOSE ACETATE AND HYALURONIC ACID EMBEDDED WITH COPPER OXIDE AND MAGNESIUM OXIDE NANOPARTICLES | September 2023 | November 2024 | Allow | 14 | 3 | 1 | Yes | No |
| 18134378 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | April 2023 | June 2024 | Allow | 14 | 2 | 0 | Yes | No |
| 18123128 | LOW-GRADE INFLAMMATION COMPOSITIONS | March 2023 | July 2025 | Allow | 28 | 3 | 0 | No | No |
| 18082353 | LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF CORONAVIRUS DISEASE AND SYMPTOMS THEREOF | December 2022 | January 2025 | Abandon | 25 | 2 | 0 | No | No |
| 17985622 | METHOD FOR ALLEVIATING CHRONIC LIVER DISEASE USING ROSOXACIN | November 2022 | March 2024 | Allow | 16 | 1 | 0 | No | No |
| 18052838 | 4-Amino Pyrimidine Compounds for the Treatment of Cancer | November 2022 | May 2025 | Allow | 40 | 3 | 0 | No | No |
| 17974000 | METHODS FOR TREATING VIRAL INFECTIONS, ORGAN INJURY, AND RELATED CONDITIONS | October 2022 | February 2025 | Abandon | 28 | 2 | 0 | No | No |
| 17969836 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TOXIC GAS EXPOSURE | October 2022 | July 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17960039 | AROMATIC IMMUNOREGULATORY COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISEASES | October 2022 | July 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 17889244 | IRON SUPPLEMENT COMPOSITIONS AND METHODS OF USE THEREOF | August 2022 | May 2025 | Abandon | 33 | 3 | 1 | No | No |
| 17567081 | METHOD, SYSTEM, FORMULATION AND KIT FOR THE TREATMENT OF ONYCHOMYCOSIS | December 2021 | January 2025 | Abandon | 37 | 2 | 0 | No | No |
| 17555736 | TREATING SAR-COV-2 RELATED HEALTH PROBLEMS | December 2021 | October 2022 | Allow | 10 | 3 | 0 | Yes | No |
| 17618687 | PROCESS FOR THE PREPARATION OF 2-FLUOROADENINE | December 2021 | April 2025 | Allow | 40 | 1 | 0 | No | No |
| 17548914 | CHEMICAL INHIBITION OF THE E3 LIGASE SUBUNIT FBXO7 CONFERS NEUROPROTECTION AND ANTI-INFLAMMATORY ACTIVITY BY STABILIZING MITOCHONDRIA | December 2021 | April 2025 | Allow | 40 | 1 | 0 | No | No |
| 17544641 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17543245 | COMPOSITIONS AND METHODS FOR CANCER THERAPY | December 2021 | June 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17612951 | (R)-3-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | November 2021 | April 2025 | Allow | 41 | 1 | 0 | No | No |
| 17612519 | COMPOSITION AND USE THEREOF FOR THE TREATMENT OF CUTANEOUS MASTOCYTOSIS | November 2021 | May 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17606212 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING TREATMENT-RESISTANT CANCER | October 2021 | March 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17605990 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | October 2021 | April 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17603553 | CD73 INHIBITORS | October 2021 | April 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17603091 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | October 2021 | April 2025 | Allow | 42 | 1 | 0 | No | No |
| 17437761 | THERAPEUTIC AGENT FOR CORNEAL DISEASES | September 2021 | February 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17446063 | Pantoprazole Compositions and Methods | August 2021 | May 2024 | Allow | 33 | 1 | 0 | No | No |
| 17433572 | HETEROCYCLIC COMPOUND AND AGRICULTURAL OR HORTICULTURAL FUNGICIDE | August 2021 | February 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17394572 | NEW ANTIBACTERIAL COMPOUND ISOLATED FROM PSILOXYLON MAURITIANUM AND ITS DERIVATIVES | August 2021 | October 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17428406 | NOVEL AZOBENZENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THERAPEUTIC TREATMENT ASSOCIATED WITH IONIZING RADIATIONS | August 2021 | March 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17358002 | AMINOQUINAZOLINONE AND AMINOISOQUINOLINONE DERIVATIVES AND APPLICATION THEREOF | June 2021 | May 2025 | Allow | 47 | 1 | 1 | No | No |
| 17418686 | COMPOSITION FOR SUPRESSING SECRETION OF EXTRACELLULAR VESICLES | June 2021 | June 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17418451 | A METHOD FOR TREATING SWI/SNF COMPLEX-DEFICIENT CANCERS COMPRISING GLUTATHIONE (GSH) METABOLIC PATHWAY INHIBITOR | June 2021 | November 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17416175 | NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | June 2021 | September 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17415496 | 1,3,4-OXADIAZOLES AND THEIR DERIVATIVES AS NEW ANTIFUNGAL AGENTS | June 2021 | February 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17311239 | VIBEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER SYMPTOMS | June 2021 | March 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17299361 | METHODS FOR TREATING CANCER IN MODELS HARBORING ESR1 MUTATIONS | June 2021 | June 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17293751 | PROPHYLACTIC OR THERAPEUTIC AGENT AND MEDICINAL COMPOSITION FOR IL-31-MEDIATED DISEASE | May 2021 | February 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17309200 | CANNABINOID COMPOSITIONS WITH HIGH SOLUBILITY AND BIOAVAILABILITY | May 2021 | January 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17244184 | GRANULATED PRODUCT CONTAINING ANTITUMOR AGENT | April 2021 | November 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17235120 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | April 2021 | August 2024 | Allow | 40 | 3 | 1 | Yes | No |
| 17233668 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | April 2021 | May 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17284323 | Compositions Comprising Guaifenesin and Flavour Compounds Containing an Isovanillyl Group | April 2021 | June 2025 | Allow | 50 | 4 | 0 | No | No |
| 17284112 | ANTICANCER ROCAGLAMIDE DERIVATIVES | April 2021 | February 2025 | Allow | 47 | 3 | 0 | No | No |
| 17284380 | DISINFECTING COMPOSITION FOR TOPICAL USE | April 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17284306 | USNIC ACID DERIVATIVE HAVING TSLP SECRETION INHIBITORY ABILITY AND USE THEREOF | April 2021 | July 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17283767 | DIHYDROIMIDAZOPYRAZINONE COMPOUND, COMPOSITION INCLUDING SAME, AND USE THEREOF | April 2021 | February 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17282058 | COMBINATION THERAPIES | April 2021 | October 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17279554 | METHOD FOR IMPROVING STABILITY OF LOW-CONCENTRATION ATROPINE OPHTHALMIC PREPARATION | March 2021 | January 2025 | Allow | 46 | 2 | 0 | No | No |
| 17277603 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | March 2021 | July 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17254048 | (3S)- AND (3R)-6,7-BIS(HYDROXYMETHYL)-1H,3H-PYRROLO[1,2-C]THIAZOLES AS P53 ACTIVATORS | December 2020 | April 2025 | Allow | 52 | 3 | 0 | No | No |
| 17059378 | NITROIMIDAZOLE FORMULATIONS | November 2020 | July 2024 | Allow | 43 | 1 | 0 | No | No |
| 17045697 | CANCER SERUM BIOMARKERS AND METHODS OF USE THEREOF | October 2020 | September 2024 | Abandon | 48 | 1 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner ROBINSON, MIKHAIL O'DONNEL works in Art Unit 1627 and has examined 51 patent applications in our dataset. With an allowance rate of 49.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner ROBINSON, MIKHAIL O'DONNEL's allowance rate of 49.0% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ROBINSON, MIKHAIL O'DONNEL receive 1.61 office actions before reaching final disposition. This places the examiner in the 43% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by ROBINSON, MIKHAIL O'DONNEL is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +63.4% benefit to allowance rate for applications examined by ROBINSON, MIKHAIL O'DONNEL. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 38.5% of applications are subsequently allowed. This success rate is in the 85% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 37.5% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 16.0% of allowed cases (in the 91% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.